Recombinant Human FSTL3/FLRG protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0949



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human FSTL3 protein Met27-Val263 (Accession# O95633-1) with a His tag at the C-terminus.
GeneID 10272
Accession O95633-1
PredictedSize 26.0 kDa
SDS-PAGE 30-36 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Follistatin-like 3 (FSTL3), also called follistatin-related protein or follistatin-related gene (FLRG) protein, is a highly conserved monomer secreted glycoprotein located on chromosome 19p13.3. The FSTL3 gene is the target of a novel chromosomal rearrangement discovered by Hayette et al in 1998 in B cells of patients with chronic lymphocytic leukemia. FSTL3 can modulate target gene expression via members of the transforming growth factor β (TGF-β) superfamily. Recent literatures have revealed that FSTL3 regulates multiple biological processes, including cell differentiation, aging, obesity development, arteriosclerosis development, and tumor progression.

References:

1. S Hayette. et al. (1998) Oncogene. 16(22):2949-54. 2. Yisrael Sidis. et al. (2002) Endocrinology. 143(5):1613-24 3. Yisrael Sidis. Et al. (2005) Endocrinology. 146(1):130-6.